Oscar Health, Inc. (FRA:9VY)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.17B +120.9% |
| Revenue (ttm) | 13.41B +42.8% |
| Net Income | 482.07M |
| EPS | 1.67 |
| Shares Out | n/a |
| PE Ratio | 16.95 |
| Forward PE | 16.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 26.19 |
| Previous Close | 26.63 |
| Day's Range | 26.19 - 26.79 |
| 52-Week Range | 9.38 - 31.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Oscar Health
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health prod... [Read more]
News
As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again
Following a parade of health insurance company earnings reports this summer, stocks are rising and costs appear to be under control for now.
Oscar Health price target raised to $30 from $22 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Oscar Health (OSCR) to $30 from $22 and keeps a Neutral rating on the shares. The company’s stronger than expected Q2 results…
Oscar Health price target raised to $27 from $20 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Oscar Health (OSCR) to $27 from $20 and keeps an Equal Weight rating on the shares. While 1H26 results…
Oscar Health price target raised to $26 from $20 at UBS
UBS raised the firm’s price target on Oscar Health (OSCR) to $26 from $20 and keeps a Neutral rating on the shares.
Oscar Health price target raised to $27 from $19 at Baird
Baird raised the firm’s price target on Oscar Health (OSCR) to $27 from $19 and keeps a Neutral rating on the shares. The firm said there were alot of moving…
Oscar Health price target raised to $39 from $35 at Barclays
Barclays raised the firm’s price target on Oscar Health (OSCR) to $39 from $35 and keeps an Overweight rating on the shares post the Q2 report. The firm believes the…
Oscar Health price target raised to $25 from $13 at BofA
BofA analyst Adam Ron raised the firm’s price target on Oscar Health (OSCR) to $25 from $13 and keeps an Underperform rating on the shares. A “strong” Q2 “puts a…
GoodRx and Oscar Health Tout Tech as Consumer Needs Change
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitabilit...
Oscar Health price target raised to $39 from $35 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Oscar Health (OSCR) to $39 from $35 and keeps an Overweight rating on the shares.
Oscar Health Earnings Call Transcript: Q2 2026
Record Q2 results with 70% revenue growth and 46% membership increase drove raised 2026 guidance. MLR improved 12 points to 79.2%, SG&A hit a record low, and technology initiatives fueled operational leverage and cost savings.
Oscar Health Earnings release: Q2 2026
Oscar Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Oscar Health Quarterly report: Q2 2026
Oscar Health has published its Q2 2026 quarterly earnings report on August 6, 2026.
Oscar Health Reports Another Big Profit As Obamacare Member Costs Ease
Health insurer Oscar Health swung to a $361 million second quarter profit while eclipsing $1 billion in net income for the first six months of the year as health plan membership rose and medical costs...
Oscar Health reports Q2 EPS $1.10, consensus 38c
Reports Q2 revenue $4.88B, consensus $4.75B. “Oscar delivered record profitability in the first half of the year and we are raising our full-year 2026 guidance,” said Mark Bertolini, CEO. “Our…
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook
NEW YORK--(BUSINESS WIRE)--Oscar Health announces strong 2Q 2026 results with significant year-over-year improvement across all core metrics.
Oscar Health price target raised to $36 from $26 at Piper Sandler
Piper Sandler raised the firm’s price target on Oscar Health (OSCR) to $36 from $26 and keeps an Overweight rating on the shares. Oscar Health appears insulated from broader Marketplace…
Oscar Health, Inc. to Host 2026 Investor Day
NEW YORK--(BUSINESS WIRE)--Oscar Health will host its 2026 Investor Day on Wednesday, September 16, 2026.
Baird sees healthcare exchange adjustment as favorable for Centene, Oscar
Baird believes the 2025 healthcare exchange risk adjustment factor true-up looks favorable for Centene (CNC) and Oscar Health (OSCR), and a “slight headwind” for Molina Healthcare (MOH). Baird sees th...
Barclays upgrades Oscar Health on exposure to individual ACA market
Barclays analyst Andrew Mok upgraded Oscar Health (OSCR) to Overweight from Equal Weight with a price target of $35, up from $30. The firm says that with “single-line exposure” to…
Oscar Health upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Andrew Mok upgraded Oscar Health (OSCR) to Overweight from Equal Weight with a $35 price target
Oscar Health Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026 performance is strong, with favorable utilization and lighter-than-expected market morbidity. Product strategy and risk management are benefiting from conservative planning, while regulatory changes and market exits shape the outlook for 2027. AI-driven integrity measures support a stable marketplace.
Oscar Health Transcript: AGM 2026
The meeting covered board transitions, strong 2025 financial results with $11.7B revenue, and a near doubling of market share to 30%. All proposals, including director elections and auditor ratification, passed. No questions were submitted during the Q&A.